The company's end-to-end approach to RNA Gene Therapy includes a proprietary suppressor technology, precision RNA editing technology, and an engineered adeno-associated virus (AAV) platform. ShapeTX's breakthrough payload, delivery, and manufacturing platform technologies potentially enable the development of cures for neurodegenerative, metabolic, and rare genetic diseases. By merging innovations in AI and RNA technology, ShapeTX is pioneering the field of programmable RNA medicines to repair the genetic causes of diseases. The company's platform enables pharma innovators to design treatments across a wide range of diseases, including rare genetic disorders as well as debilitating conditions, such as Alzheimer’s, Parkinson’s, and many more.